Corpus Intelligence IC Memo — UT HEALTH EAST TEXAS REHAB HOSPITAL 2026-04-26 08:50 UTC
IC Memo — UT HEALTH EAST TEXAS REHAB HOSPITAL
Investment Committee Memorandum | TX | 49 beds | Grade D | EBITDA uplift $2.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UT HEALTH EAST TEXAS REHAB HOSPITAL

CCN 453072 | SMITH, TX | 49 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

UT HEALTH EAST TEXAS REHAB HOSPITAL is a 49-bed community hospital in SMITH, TX with $30.5M in net patient revenue and a -8.4% operating margin. The hospital serves a payer mix of 46.8% Medicare, 0.0% Medicaid, and 53.2% commercial.

Thesis: Turnaround. Our ML models identify $2.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -8.4% to -1.1% (+736bps).

Net Revenue HCRIS$30.5M
Current EBITDA COMPUTED$-2.6M
Operating Margin COMPUTED-8.4%
Occupancy HCRIS60.4%
Revenue / Bed COMPUTED$622K
Net-to-Gross HCRIS18.9%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
271
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -8.4% places it below the state median. Among 271 size-comparable peers (24-98 beds), the median margin is -3.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (24-98), prioritizing same-state peers. 271 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UT HEALTH EAST TEXAS REHAB HOS (Target)TX49$30.5M-8.4%
DECATUR COMMUNITY HOSPITALTX81$361.0M-15.5%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CHILDRENS MEDICAL CENTER OF PLTX72$336.7M20.9%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
BAYLOR HEART AND VASCULAR HOSPTX53$255.0M30.0%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
LAKE GRANBURY MEDICAL CENTERTX53$181.6M38.5%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$640K+210bp18mo
Cost to Collect4.5%2.5%$610K+200bp12mo
Denial Rate Reduction12.0%6.5%$604K+198bp12mo
A/R Days Reduction5200.0%3800.0%$371K+122bp9mo
Clean Claim Rate88.0%96.0%$20K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$640K
Cost to Collect
$610K
Denial Rate Reduction
$604K
A/R Days Reduction
$371K
Clean Claim Rate
$20K
Total EBITDA Uplift$2.2M
Current EBITDA$-2.6M
+ RCM Uplift+$2.2M
Pro Forma EBITDA$-323K
Current Margin-8.4%
Pro Forma Margin-1.1%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-3.9M$5.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-3.9M$4.8M0.00x-100.0%
Bull Case9.0x11.0x$-3.6M$10.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.6M$10.8M0.00x-100.0%
Bear Case11.0x10.0x$-4.3M$-4.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.3M$-6.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 271 hospitals with 24-98 beds
  • Same-state prioritization (n=272)
  • Comp margins: P25=-21.1% / P50=-3.1% / P75=10.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.